Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature reviewShunan Wang, Ou Bai, Xiaoge Zhou et al.|Therapeutics and Clinical Risk Management|2018Cited by 4
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 studyYuankai Shi, Yongping Song, Dong Wang et al.|BMC Cancer|2024Cited by 4
LBA2 | ZANUBRUTINIB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS R‐miniCHOP IN UNFIT OR FRAIL PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA AGED 70 YEARS OR OLDERPeng Xu, Zhenwei Shi, Fei Li et al.|Hematological Oncology|2025Cited by 2